To read the file of this research, you can request a copy directly from the authors.
Abstract
BEST HOPE is a project to construct a cohort of newly diagnosed HIV patients in Portugal: BEST HOPE aims are: 1) to analyze the prevalence and characteristics of TDR in newly diagnosed HIV patients, and 2) to describe and analyze risk factors associated with HIV infection and transmission of drug resistance in Portugal.
Background
Portugal has one of the most severe HIV-1 epidemics in Western Europe. Two subtypes circulate in parallel since the beginning of the epidemic. Comparing their transmission patterns and its association with transmitted drug resistance (TDR) is important to pinpoint transmission hotspots and to develop evidence-based treatment guidelines.
Methods
Demographic, clinical and genomic data were collected from 3599 HIV-1 naive patients between 2001 and 2014. Sequences obtained from drug resistance testing were used for subtyping, TDR determination and transmission clusters (TC) analyses.
Results
In Portugal, transmission of subtype B was significantly associated with young males, while transmission of subtype G was associated with older heterosexuals. In Portuguese originated people, there was a decreasing trend both for prevalence of subtype G and for number of TCs in this subtype. The active TCs that were identified (i.e. clusters originated after 2008) were associated with subtype B-infected males residing in Lisbon. TDR was significantly different when comparing subtypes B (10.8% [9.5–12.2]) and G (7.6% [6.4–9.0]) (p = 0.001).
Discussion
TC analyses shows that, in Portugal, the subtype B epidemic is active and fueled by young male patients residing in Lisbon, while transmission of subtype G is decreasing. Despite similar treatment rates for both subtypes in Portugal, TDR is significantly different between subtypes.
750-9. 3-TenoRes Study Group
Jan 2007
1001810-1001812
Sy Rhee
Rhee SY, et al. (2015). PLoS Med 12(4): e1001810. 2-Hamers RL, et al. (2011)
Lancet Infect Dis 11(10):750-9. 3-TenoRes Study Group. (2016). Lancet Infect Dis
16(5):565–75. 4-Abecasis AB, et al. (2013). Retrovirology 10:36. 5-Frentz D, et al.
(2014) PLoS ONE 9(4): e94495. 6-Palma AC, et al. (2007) Infection, Genetics and
Evolution (7) 391-398.